Patents by Inventor Riccardo Cortese
Riccardo Cortese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075125Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.Type: ApplicationFiled: May 22, 2023Publication date: March 7, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11913013Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: GrantFiled: July 30, 2021Date of Patent: February 27, 2024Assignee: SABIN VACCINE INSTITUTEInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 11701422Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.Type: GrantFiled: February 25, 2020Date of Patent: July 18, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11498956Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.Type: GrantFiled: August 23, 2017Date of Patent: November 15, 2022Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, UNIVERSITY OF COPENHAGENInventors: Maria Rosaria Bassi, Riccardo Cortese, Anna Morena D'Alise, Antonella Folgori, Peter Johannes Holst, Alfredo Nicosia
-
Publication number: 20220220157Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: January 25, 2022Publication date: July 14, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
-
Publication number: 20220204566Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: December 30, 2021Publication date: June 30, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra Franz VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Patent number: 11278614Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: GrantFiled: February 5, 2020Date of Patent: March 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
-
Publication number: 20220064669Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: July 30, 2021Publication date: March 3, 2022Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 11254711Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: GrantFiled: June 10, 2016Date of Patent: February 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefano Colloca, Riccardo Cortese, Fabiana Grazioli, Alfredo Nicosia, Alessandra Vitelli
-
Patent number: 11254710Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: GrantFiled: June 10, 2016Date of Patent: February 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Virginia Ammendola, Fabiana Grazioli, Alessandra Franz Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11214599Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: GrantFiled: December 11, 2019Date of Patent: January 4, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
-
Publication number: 20210060150Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.Type: ApplicationFiled: August 6, 2020Publication date: March 4, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Publication number: 20200360509Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.Type: ApplicationFiled: February 25, 2020Publication date: November 19, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Publication number: 20200164061Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: ApplicationFiled: February 5, 2020Publication date: May 28, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano COLLOCA, Riccardo CORTESE, Antonella FOLGORI, Alfredo NICOSIA
-
Publication number: 20200149069Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: January 24, 2020Publication date: May 14, 2020Applicants: The Government of the United States of America as Represented by the Secretary of the Department of, GlaxoSmithKline Biologicals SAInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Publication number: 20200140886Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: June 10, 2016Publication date: May 7, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
-
Publication number: 20200102352Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: ApplicationFiled: December 11, 2019Publication date: April 2, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
-
Patent number: 10588961Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: GrantFiled: December 20, 2017Date of Patent: March 17, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
-
Patent number: 10584355Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: GrantFiled: October 31, 2016Date of Patent: March 10, 2020Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 10576143Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.Type: GrantFiled: March 17, 2017Date of Patent: March 3, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia